Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects With Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04406623
• Other study ID #: SL03-OHD-101
• Status: Completed
• Phase: Phase 1
• Start date: June 29, 2020
• Est. completion date: February 2, 2023

Study information

• Verified date: May 2023
• Source: Shattuck Labs, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.

Description:

This Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor and pharmacodynamic effects of SL-172154 and identify the dose and schedule i.e., recommended Phase 2 dose for future development (RP2D). Subjects eligible for enrollment are required to have platinum-ineligible ovarian, fallopian tube, and primary peritoneal cancers. The study design consists of dose escalation cohorts, an optional pharmacodynamic cohort, and an optional dose expansion cohort. In the dose escalation phase of the study, subjects will be enrolled into sequential dose levels. The study may also enroll a pharmacodynamic cohort to obtain additional pharmacodynamic data at one or more dose levels that have completed evaluation for safety without exceeding the maximum tolerated dose (MTD). Subjects enrolled in the pharmacodynamic cohort will not inform dose escalation decisions. A dose expansion cohort may be opened to further characterize safety, tolerability, PK, anti-tumor activity, and pharmacodynamic data to inform the selection of a RP2D.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: February 2, 2023
• Est. primary completion date: February 2, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.

2. Subject must have a histologically confirmed diagnosis of an unresectable, locally advanced or metastatic ovarian cancer, or primary peritoneal cancer or fallopian tube cancer.

3. Subjects must be refractory or intolerant to existing therapy(ies) known to provide clinical benefit for their condition. Subject must have received platinum-based therapies, and should not be eligible for further platinum therapy, or should be intolerant to such therapy. Subjects with HRD positive disease may participate if they have received prior polyadenosine diphosphate ribose polymerase (PARP) inhibitor therapy given alone or with bevacizumab.

4. Subjects should not be primary platinum refractory as defined by progressing during or within 1 month of upfront platinum therapy.

5. Has measurable disease by RECIST v1.1 using radiologic assessment.

6. Subject age is 18 years and older.

7. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

8. Has life expectancy of greater than 12 weeks.

9. Has adequate organ function.

10. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP.

11. Recovery from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or = Grade 1.

12. Willing to consent to mandatory pre-treatment and on-treatment tumor biopsy(ies), unless there is excessive risk as determined by the investigator.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

1. Prior treatment with an anti-CD47 or anti-SIRPa targeting agent or a CD40 agonist.

2. Any anti-cancer therapy within the washout period prior to first dose (D1) of SL-172154.

3. Concurrent chemotherapy, immunotherapy, biologic or hormonal/hormonal suppression therapy for cancer treatment is prohibited. Concurrent use of hormones for non-cancer related conditions is acceptable.

4. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of D1 of SL-172154 treatment.

5. Receipt of live attenuated vaccine within 28 days of D1 of IP.

6. Active or documented history of autoimmune disease. Exceptions include controlled Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism.

7. Hypersensitivity to the active drug substance or to any of the excipients for the agent to be administered or subjects with known hypersensitivity to Chinese hamster ovary cell products.

8. Active pneumonitis (i.e. drug-induced, idiopathic pulmonary fibrosis, radiation-induced, etc.).

9. Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of IP).

10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal disease associated with diarrhea within 6 months of D1 of IP.

11. Clinically significant or uncontrolled cardiac/thromboembolic disease.

12. Untreated central nervous system or leptomeningeal metastases.

13. Women who are breast feeding.

14. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent.

15. Another malignancy that requires active therapy and that in the opinion of the investigator and Sponsor would interfere with monitoring of radiologic assessments of response to IP.

16. Has undergone allogeneic stem cell transplantation or organ transplantation.

17. Known history or positive test for human immunodeficiency virus, or positive test for hepatitis B.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Ovarian Neoplasms
• Primary Peritoneal Carcinoma

Intervention

Drug:
• SL-172154
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPa and CD40L (SIRPa -Fc-CD40L) linked via a human Fc.

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	City of Hope	Duarte	California
United States	START Midwest	Grand Rapids	Michigan
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Stephenson Cancer Center at Oklahoma University	Oklahoma City	Oklahoma
United States	START Mountain Region	West Valley City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Shattuck Labs, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile of SL-172154	Incidence of all treatment emergent adverse events	From Day 1 to 90 days after Last Dose of SL-172154
Primary	Maximum Tolerated Dose (MTD) of SL-172154	Defined based on the rate of dose limiting toxicities (DLTs)	From Day 1 to 90 days after Last Dose of SL-172154
Secondary	Establish the recommended Phase 2 dose (RP2D) for SL-172154	Establish the RP2D for SL-172154	Approximately 24 months
Secondary	Assess preliminary evidence of anti-tumor activity of SL-172154	Disease assessment per investigator assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)	Approximately 24 months
Secondary	Immunogenicity to SL-172154	Number and proportion of participants with positive anti-drug antibody titer	Approximately 24 months
Secondary	Maximum serum concentration (Cmax) of SL-172154	The Cmax is the maximum observed serum concentration of SL-172154 following single and multiple doses	Approximately 24 months
Secondary	Minimum serum concentration (Cmin) of SL-172154	The Cmin is the minimum observed serum concentration of SL-172154 following single and multiple doses	Approximately 24 months
Secondary	Time at which maximum concentration of SL-172154 is observed (Tmax)	The Tmax is the time at which the maximum concentration of SL-172154 is observed following single and multiple doses	Approximately 24 months
Secondary	Area under the serum concentration-time curve (AUC)	The AUC is the area under the serum concentration time curve following single and multiple doses of SL-172154	Approximately 24 months
Secondary	Terminal elimination half-life (t1/2)	Terminal elimination half-life (t1/2) of SL-172154	Approximately 24 months
Secondary	Clearance (CL)	Clearance of Sl-172154	Approximately 24 months
Secondary	Volume of distribution	Volume of distribution of SL-172154	Approximately 24 months